Hepion Pharmaceuticals Files 2023 Annual Report Amendment
Ticker: CTRVP · Form: 10-K/A · Filed: Jan 13, 2025 · CIK: 1583771
| Field | Detail |
|---|---|
| Company | Hepion Pharmaceuticals, Inc. (CTRVP) |
| Form Type | 10-K/A |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.0001, $50 million, $400,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
Related Tickers: HEPN
TL;DR
Hepion Pharma (HEPN) filed its amended 2023 10-K on Jan 13, 2025. Check for updates.
AI Summary
Hepion Pharmaceuticals, Inc. filed an amendment (No. 2) to its 2023 annual report on January 13, 2025. The company, formerly ContraVir Pharmaceuticals, Inc., is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal business address is in Edison, NJ.
Why It Matters
This filing provides updated information for the fiscal year ending December 31, 2023, which is crucial for investors to assess the company's financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine amendment to a previously filed annual report, not indicating new material adverse events.
Key Numbers
- 2023 — Fiscal Year End (The report covers the annual period ending December 31, 2023.)
- January 13, 2025 — Filing Date (This is the date the amendment was filed with the SEC.)
Key Players & Entities
- Hepion Pharmaceuticals, Inc. (company) — Registrant
- ContraVir Pharmaceuticals, Inc. (company) — Former Company Name
- 2023 (date) — Fiscal Year End
- January 13, 2025 (date) — Filing Date
- Delaware (location) — State of Incorporation
- Edison, NJ (location) — Business Address
FAQ
What is the purpose of this 10-K/A filing?
This filing is Amendment No. 2 to Hepion Pharmaceuticals, Inc.'s annual report for the year ended December 31, 2023.
When was this amendment filed?
The amendment was filed on January 13, 2025.
What was Hepion Pharmaceuticals, Inc. formerly known as?
Hepion Pharmaceuticals, Inc. was formerly known as ContraVir Pharmaceuticals, Inc.
In which state is Hepion Pharmaceuticals, Inc. incorporated?
The company is incorporated in Delaware.
What is the company's primary business address?
The company's business address is 399 Thornall Street, First Floor, Edison, NJ 08837.
Filing Stats: 4,530 words · 18 min read · ~15 pages · Grade level 12.1 · Accepted 2025-01-13 07:00:20
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share The Nasdaq Capital Market
- $50 million — nce 2006, has led or "co-led" more than $50 million in research funding. Honors include an
- $400,000 — r. Cavan's current base compensation is $400,000 per year. Mr. Cavan is eligible to rece
Filing Documents
- form10-ka.htm (10-K/A) — 228KB
- ex31-1.htm (EX-31.1) — 13KB
- ex31-2.htm (EX-31.2) — 16KB
- ex32-1.htm (EX-32.1) — 7KB
- ex32-2.htm (EX-32.2) — 7KB
- form10-ka_001.jpg (GRAPHIC) — 2KB
- 0001493152-25-001857.txt ( ) — 520KB
- hepa-20231231.xsd (EX-101.SCH) — 3KB
- hepa-20231231_lab.xml (EX-101.LAB) — 35KB
- hepa-20231231_pre.xml (EX-101.PRE) — 23KB
- form10-ka_htm.xml (XML) — 7KB
Executive Compensation
Executive Compensation 7 Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 9 Item 13. Certain Relationships and Related Transactions, and Director Independence 9 Item 14. Principal Accounting Fees and Services 9 PART IV Item 15. Exhibits and Financial Statement Schedules 10
SIGNATURES
SIGNATURES 12 2 PART III Item 10. Directors, Executive Officers and Corporate Governance. Executive Officers and Directors Set forth below is certain information with respect to the individuals who are our directors and executive officers as of June 20, 2024: Name Age Position(s) John Cavan 65 Interim Chief Executive Officer and Chief Financial Officer John P. Brancaccio 76 Executive Chairman Timothy Block, Ph.D. 68 Director Kaouthar Lbiati, M.D. 45 Director Michael Purcell 67 Director John Cavan has been our interim Chief Executive Officer since December 2023 and Chief Financial Officer since March 2016. Previously, Mr. Cavan was a consultant with The Pine Hill Group where he was instrumental in completing several financial transactions, including initial public offerings, business combinations and strategic transactions. Prior to his role with the Pine Hill Group, he served as Chief Accounting Officer at Stemline Therapeutics, Inc. Preceding his role at Stemline, Mr. Cavan was Vice President and Chief Accounting Officer at Aegerion Pharmaceuticals, Inc. He has also held financial positions within the healthcare industry at AlgoRx Pharmaceuticals, Inc. and Alpharma. Mr. Cavan served in a variety of financial and operational positions early in his career during tenures with large multinational public companies, including Sony, American Express, International Specialty Products (an Ashland Company) and Nestl U.S.A. Mr. Cavan currently serves on the Board of Directors of Vantage Health Systems. He holds a B.B.A in Accountancy from Iona College and an M.B.A. in Finance from Seton Hall University. John P. Brancaccio, a retired CPA, has served as Executive Chairman since March 2024 and a director of our Company since May 15, 2013. Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies from April 2004 until May 2017. Mr. Brancaccio served as a director